Effect of Alpha1 Antitrypsin, PD-1/PD-L1 or and EGFR in Colitis-Associated Colorectal Cancer BALB/c Mouse Model

Articles in Press

Document Type : Research Articles

Authors

1 Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan.

2 Department of Biological Sciences, Faculty of Science, Yarmouk University, Irbid, Jordan.

Abstract

Objective: This study aimed to investigate whether Human alpha-1 antitrypsin affects Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) as well as epidermal growth factor receptor (EGFR) expression using a colon cancer tissues in chemically induced colorectal cancer (CRC) model. Previous study indicated a protective role of AAT administration on the development of cancer in CRC mouse model. Methodology: The expression of PD1/PDL1 and EGFR were analyzed in colon cancer tissue collected from (AOM/DSS) CRC mice using both real time gene expression (qPCR) and immunohistochemistry(IHC). Results: Study results showed that AAT treatment reduced PD-L1 protein expression by 63.5% (mean H score: 7.8±1.3 to 2.85±0.85, p=0.0004) and EGFR protein expression by 48.9% (mean H score: 1.78±0.76 to 0.91±0.60, p=0.04) in the tissue of AOM/DSS-treated mice. In addition, AAT treatment controlled PD1 gene expression and repressed EGFR gene expression by 1.4-fold compared to DSS samples. Immunohistochemical analysis revealed various degrees of PD1 protein expression, and CD4 and CD8 positive lymphocytes were found in the tumor microenvironment. Conclusion: These findings suggest that AAT treatment has immunomodulatory properties and may represent a promising therapeutic strategy for colon cancer.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention

Articles in Press, Accepted Manuscript
Available Online from 12 September 2025

Files

History

  • Receive Date: 01 November 2024
  • Revise Date: 01 June 2025
  • Accept Date: 01 September 2025

Share

How to cite

Statistics